Skip to main content
. 2022 Jun 21;2022(6):CD006404. doi: 10.1002/14651858.CD006404.pub4

Sagara 2018 (Ouagadougou, Burkina Faso).

Study characteristics
Methods RCT* ‐ represents disaggregated data from Sagara 2018 (see above)
Participants Number receiving at least 1 study treatment: 429
Interventions
  • Pyronaridine‐artesunate (n = 215)

  • Amodiaquine‐artesunate (n = 214)

Outcomes
Notes Location: Ouagadougou, Burkina Faso
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence generation (selection bias) Low risk Represents disaggregated data from Sagara 2018 (see above)
Allocation concealment (selection bias) Low risk
Blinding (performance bias and detection bias)
All outcomes Low risk
Incomplete outcome data (attrition bias)
All outcomes Low risk
Selective reporting (reporting bias) Low risk
Other bias Low risk
Adverse event monitoring (detection bias)
Adverse events Low risk
Incomplete adverse event reporting (reporting bias)
Adverse events Low risk